Natural killer (NK) cells play a critical role in the body's immune system. Their unique ability to identify and destroy abnormal cells, while leaving healthy cells unharmed, make them a promising treatment option for various cancers and infectious diseases. NK and CAR-NK cells represent an attractive alternate modality with the potential to address shortcomings experienced by T cell and CAR T-based therapies. NK cell therapies also offer impressive feasibility as an off-the-shelf product, an enhanced safety profile with respect to cytokine release syndrome, neurotoxicity and graft-versus-host disease, and renewed promise where T cells have fallen short in the solid tumour setting.
In this webinar, we will: